Prader-Willi syndrome: Symptoms and topiramate response in light of genetics.
Prader–Willi
deletion
disomy
genetics
personalized medicine
topiramate
treatment
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
12
2022
accepted:
17
01
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
Prader-Willi Syndrome (PWS) is a rare genetic condition, which affects one in 25,000 births and results in various phenotypes. It leads to a wide range of metabolic and endocrine disorders including growth delay, hypogonadism, narcolepsy, lack of satiety and compulsive eating, associated with mild to moderate cognitive impairment. Prognosis is especially determined by the complications of obesity (diabetes, cardiorespiratory diseases) and by severe behavioral disorders marked by impulsivity and compulsion. This heterogeneous clinical picture may lead to mis- or delayed diagnosis of comorbidities. Moreover, when diagnosis is made, treatment remains limited, with high interindividual differences in drug response. This may be due to the underlying genetic variability of the syndrome, which can involve several different genetic mutations, notably deletion or uniparental disomy (UPD) in a region of chromosome 15. Here, we propose to determine whether subjects with PWS differ for clinical phenotype and treatment response depending on the underlying genetic anomaly. We retrospectively included all 24 PWS patients who were referred to the Reference Center for Rare Psychiatric Disorders (GHU Paris Psychiatrie and Neurosciences) between November 2018 and July 2022, with either deletion ( First, we found that disomy was associated with a more severe clinical phenotype than deletion. Second, we observed that topiramate was less effective and less tolerated in disomy, compared to deletion. These results suggest that a pharmacogenomic-based approach may be relevant for the treatment of compulsions in PWS, thus highlighting the importance of personalized medicine for such complex heterogeneous disorders.
Identifiants
pubmed: 36814790
doi: 10.3389/fnins.2023.1126970
pmc: PMC9939745
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1126970Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 Louveau, Turtuluci, Consoli, Poitou, Coupaye, Krebs, Chaumette and Iftimovici.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pediatr Neurol. 2003 Feb;28(2):130-3
pubmed: 12699864
Lancet Diabetes Endocrinol. 2021 Apr;9(4):235-246
pubmed: 33647242
Res Dev Disabil. 2011 Sep-Oct;32(5):1729-35
pubmed: 21454045
Ital J Pediatr. 2022 Jul 23;48(1):121
pubmed: 35870983
Ther Adv Psychopharmacol. 2021 Oct 09;11:20451253211046765
pubmed: 34646440
Epilepsy Behav. 2021 May;118:107939
pubmed: 33839453
CNS Drugs. 2003;17(3):167-78
pubmed: 12617696
Ment Health Clin. 2018 Mar 23;7(1):7-9
pubmed: 29955490
Lancet Psychiatry. 2018 Apr;5(4):370-378
pubmed: 29352661
Pediatrics. 2001 Nov;108(5):E92
pubmed: 11694676
Int J Mol Sci. 2021 Mar 08;22(5):
pubmed: 33800122
Orphanet J Rare Dis. 2022 Aug 26;17(1):324
pubmed: 36028863
Ann Pharmacother. 2013 Mar;47(3):340-9
pubmed: 23482732
Curr Pediatr Rev. 2019;15(4):207-244
pubmed: 31333129
Handb Clin Neurol. 2021;181:351-367
pubmed: 34238470
Med Clin North Am. 2018 Jan;102(1):135-148
pubmed: 29156182
Neurosci Biobehav Rev. 2018 Dec;95:396-405
pubmed: 30392879
Endokrynol Pol. 2022;73(1):35-42
pubmed: 35381103
Profiles Drug Subst Excip Relat Methodol. 2019;44:333-378
pubmed: 31029222
Clin Genet. 2005 Jan;67(1):47-52
pubmed: 15617548
Rare Dis. 2013 Mar 27;1:e24421
pubmed: 25002992
Case Rep Psychiatry. 2021 Oct 11;2021:2527261
pubmed: 34671495
Tijdschr Psychiatr. 2021;63(6):432-440
pubmed: 34231862
Orphanet J Rare Dis. 2015 Sep 02;10:106
pubmed: 26329144
Eur Psychiatry. 2017 Jul;44:47-52
pubmed: 28545008
J Child Psychol Psychiatry. 2005 Oct;46(10):1089-96
pubmed: 16178933
Ther Clin Risk Manag. 2016 Jun 02;12:873-81
pubmed: 27330297
Am J Ment Retard. 2004 Jul;109(4):301-9
pubmed: 15176917
J Neuroendocrinol. 2021 Jul;33(7):e12994
pubmed: 34156126
Endocrinol Diabetes Nutr (Engl Ed). 2019 Nov;66(9):579-587
pubmed: 31006652
Ann Pediatr Endocrinol Metab. 2013 Dec;18(4):161-7
pubmed: 24904871
Genet Med. 2012 Jan;14(1):10-26
pubmed: 22237428
Pediatrics. 2004 Mar;113(3 Pt 1):565-73
pubmed: 14993551
Int J Neuropsychopharmacol. 2002 Jun;5(2):141-5
pubmed: 12135538
Mol Psychiatry. 2021 Jan;26(1):51-59
pubmed: 33082508
Transl Psychiatry. 2019 Nov 4;9(1):274
pubmed: 31685813
Endocr Connect. 2022 Dec 15;12(1):
pubmed: 36347048